arrow
D

Dongrui Wang

zhejiang university school of medicine
H指数:24
被引数:3,750

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to <Long-Term Follow-Up of CD19 CAR-T for R/R B-NHL: Ki-67 as a Prognostic Factor for Sustained Remission> <[Transplantation and cellular therapy, 32(8), 952.e1–952.e15.]>

勘误:&lt;CD19 CAR-T治疗复发/难治性B-NHL的长期随访:Ki-67作为持续缓解的预后因素&gt; &lt;[移植与细胞治疗, 32(8), 952.e1–952.e15.]&gt;

2026-09-240
OA
Sonication-induced J-aggregation in nonhalogenated solvents boosts exciton delocalization for high-efficiency organic solar cells

非卤化溶剂中超声诱导的J聚集增强了激子离域,从而提高了有机太阳能电池的效率。

2025-11-250
OAAI
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial

CD19靶向和BCMA靶向CAR-T细胞的联合输注治疗难治性系统性红斑狼疮:一项1期临床试验

2025-09-240
PRE
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety

氯毒素靶向的CAR T细胞疗法治疗复发性胶质母细胞瘤:中期临床经验表明其可行性和安全性

2025-08-150
PREAI
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial

达沙替尼和CAR T细胞疗法在初诊费城染色体阳性急性淋巴细胞白血病中的应用:一项非随机临床试验

2025-04-170
PRE
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial (JUNE, 10.1038/s41591-024-02875-1, 2023)
2024-03-210
OAAI
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

Il-13rα2靶向car-t细胞在复发性高级别胶质瘤中的局部区域递送: 1期试验

2024-03-0751
OAAI
Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial

供体来源的Anti-CD19 CAR T细胞GC007g治疗异基因HSCT后复发或难治性b细胞急性淋巴细胞白血病: 1期试验

2024-01-017
OAAI
Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in- human phase I study

基于CRISPR的非病毒PD1位点特异性整合anti-CD19 car-t细胞治疗复发或难治性非霍奇金淋巴瘤的安全性和有效性: 首次人体I期研究

2023-06-0125
OAAI